Invited Speakers

Memorial Lecture

  • ML01 Regulation of PCNA for Proper DNA Replication and Suppression of Genomic Instability Prof. Kyungjae Myung UNIST / Institute for Basic Science, Korea CV
  • ML02 Biological Heterogeneity of AML: Implications for Prognosis and Treatment Prof. Clara Bloomfield The Ohio State University, USA CV
  • ML03 Approaching Survival of the General Population: The Results of CML Study IV in the Global Context Prof. Rüdiger Hehlmann Heidelberg University, Germany CV
  • ML04 New Models of Human Leukemia Dr. Connie Eaves British Columbia Cancer part of Provincial Health Services Authority, Canada CV
  • ML05 Integrating CAR T-Cell Therapy into the Treatment of Lymphoma, Myeloma, and Leukemia: Strategies for Maximizing Patient Outcomes Prof. David G. Maloney Fred Hutchinson Cancer Research Center, USA CV
  • ML06 Leukemia Stem Cell and Bone Marrow Microenvironment Interactions Prof. Ravi Bhatia The University of Alabama at Birmingham, USA CV
  • ML07 Understanding Evolution and Outcomes in Myeloproliferative Neoplasms Dr. Jyoti Nangalia Wellcome Sanger Institute, UK CV

Keynote Speech

  • KS Treatment of Adult T-cell Leukemia (ATL) and a Novel Epigenetic Drug against ATL Prof. Toshiki Watanabe The University of Tokyo, Japan CV

Session 1: Virus Associated Hematologic Malignancies

  • SY01-1 HTLV-1/BLV Genomic Approaches to Understanding Adult T-cell Leukemia Dr. Anne Van den Broeke Jules Bordet Institute - ULB, Belgium CV
  • SY01-2 Hydroa-vacciniforme-like Lymphoproliferative Disease: A Cutaneous Form of CAEBV Prof. Young-Hyeh Ko Sungkyunkwan University, Korea CV
  • SY01-3 Can We Cure Adult T Cell Leukemia/Lymphoma? Prof. Ali Bazarbachi American University of Beirut-Medical Center, Lebanon CV

Session 2: Myelodysplastic Syndromes

  • SY02-1 DNA Methylation and Hydroxymethylation in Hematologic Differentiation and Transformation Prof. Myunggon Ko Ulsan National Institute of Science and Technology, Korea CV
  • SY02-2 Iron Toxicity in MDS Prof. Daniela Cilloni University of Torino, Italy CV
  • SY02-3 DDX41 Mutations in Myelodysplastic Syndrome Prof. Je-Hwan Lee University of Ulsan, Korea CV
  • SY02-4 Hypomethylation-based Combination Treatments: Where Epigenetics Meets Immunotherapy Prof. Michael Lübbert University of Freiburg Medical Center, Germany CV

Luncheon Symposium 1 [Sponsored by Bristol-Myers Squibb]

  • LS01 Recent Treatment Advances for Patients with Chronic Myeloid Leukaemia (CML): Insights from the UK SPIRIT2 Trial Prof. Richard Clark University of Liverpool, UK CV

Session 3: Acute Myeloid Leukemia

  • SY03-1 The Rapidly Evolving Field of AML Prof. Gert Ossenkoppele Amsterdam University Medical Center, location VUMC, The Netherlands CV
  • SY03-2 Curative Treatment Options for Older Patients with AML Prof. Hervé Dombret Saint-Louis Institute for Research/ University of Paris, France CV
  • SY03-3 Development of a Novel FLT3 Inhibitor Prof. Hitoshi Kiyoi Nagoya University, Japan CV
  • SY03-4 Functional Genomic Approaches to Identifying New Therapeutic Strategies for AML Prof. Jeffrey Tyner Oregon Health & Science University, USA CV

Session 4: Chronic Myeloid Leukemia

  • SY04-1 Next Generation Sequencing for Chronic Myeloid Leukemia Prof. Susan Branford Centre for Cancer Biology, SA Pathology, Australia CV
  • SY04-2 New Horizon for CML Therapy: Treatment Discontinuation (TFR) Prof. Giuseppe Saglio University of Turin, Italy CV
  • SY04-3 Novel Agents for Chronic Myeloid Leukemia Prof. Michael Mauro Memorial Sloan Kettering Cancer Center, USA CV
  • SY04-4 Allogeneic Stem Cell Transplantation in CML Prof. Eduardo Olavarria Imperial College London, UK CV

Session 5: Multiple Myeloma

  • SY05-1 Clinical and Biological Significance of RNA Editing Defect in Myeloma Prof. Wee Joo Chng National University Health System, Singapore CV
  • SY05-2 Current Approaches and Future Perspectives in the Treatment of Newly Diagnosed Myeloma Patients Prof. Roberto Mina University of Torino, Italy CV
  • SY05-3 Minimal Residual Disease: A Pitfall between Next-Generation Flow and Next-Generation Sequencing Analyses in Myeloma Prof. Dong Soon Lee Seoul National University, Korea CV

Session 6: Acute Lymphoblastic Leukemia

  • SY06-1 Analysis of CNS-ALL with Patient Derived Xenografts (PDX) Model Prof. Itaru Kato Kyoto University, Japan CV
  • SY06-2 Targeting Adhesion Molecules in B-ALL Prof. Yong-Mi Kim University of Southern California, USA CV
  • SY06-3 Minimal Residual Disease and Targeted Therapy in Acute Lymphoblastic Leukemia Prof. Dieter Hoelzer Onkologikum Frankfurt, Germany CV
  • SY06-4 Ph+ ALL in Adults Evolving Place for TKIs, Chemotherapy, Immunotherapy and Transplantation Dr. Françoise Huguet University Institute of Cancer, France CV

Luncheon Symposium 2 [Sponsored by Novartis]

  • LS02 Cutting Edge of Molecular Target Therapy and Therapeutic Strategies in CML Prof. Yosuke Minami National Cancer Center Hospital East, Japan CV

Session 7: Molecular Mechanisms

  • SY07-1 Understanding and Targeting the Stem Cell Origins of MDS and AML Prof. Ulrich Steidl Albert Einstein College of Medicine - Montefiore Medical Center, USA CV
  • SY07-2 Genetics and Mechanisms of Chemotherapy Resistance in Relapse Acute Lymphoblastic Leukemia Prof. Adolfo Ferrando Columbia University, USA CV
  • SY07-3 Clonal Origin of Cancer Prof. Seishi Ogawa Kyoto University, Japan CV
  • SY07-4 Single-cell Sequencing for Understanding Tumor Heterogeneity and Evolution Prof. Semin Lee Ulsan National Institute of Science and Technology, Korea CV

Session 8: Lymphoma/ Chronic Lymphocytic Leukemia

  • SY08-1 Molecular Predictors and Prognosticators for the Clinical Management of Chronic Lymphocytic Leukemia Prof. Gianluca Gaidano University of Eastern Piedmont, Italy CV
  • SY08-2 CLL/SLL: from Genetics to the Clinic Prof. Wei Xu Jiangsu Province Hospital, China CV
  • SY08-3 Management of NK/T-cell Lymphoid Malignancy Prof. Seok Jin Kim Samsung Medical Center, Korea CV
  • SY08-4 Targeting Chronic Lymphocytic Leukemia in the Front Line Prof. Richard A. Larson The University of Chicago, USA CV

Session 9: Myeloproliferative Neoplasms

  • SY09-1 2020 Clinical, Laboratory, Molecular and Bone Marrow (CLMB) Classification and Treatment Options of Myeloproliferative Neoplasms Prof. Jan Jacques Michiels Goodheart Institute and Foundation, The Netherlands CV
  • SY09-2 Allogeneic Hematopoietic Stem Cell Transplantation for Primary Myelofibrosis Prof. Ki-Seong Eom The Catholic University of Korea, Korea CV
  • SY09-3 Integrated Molecular Profiling of Juvenile Myelomonocytic Leukemia Prof. Hideki Muramatsu Nagoya University, Japan CV

Session 10: Leukemia Researches in Asian Sector

  • SY10-1 Study of Hematopoiesis Using Zebrafish Model System Dr. Yoonsung Lee UNIST / Institute for Basic Science, Korea CV
  • SY10-2 Nutrient Supply Specific to Chronic Myelogenous Leukemia Stem Cells Dr. Kazuhito Naka Hiroshima University, Japan CV
  • SY10-3 Progress of CAR-T Cell Therapy for Hematological Malignancies in China Prof. Xiaojun Huang Peking University People's Hospital, China CV
  • SY10-4 CAR T Cells in Hematologic Malignancies: What’s Next? Prof. Jae Park Memorial Sloan Kettering Cancer Center, USA CV